30 December 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
Hemogenyx Pharmaceuticals
Opens First Clinical Site for HG-CT-1 Phase I
Trial
Patient Recruitment Begins
for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid
Leukemia in Adults
Hemogenyx Pharmaceuticals plc (LSE:
HEMO) is pleased to announce the opening of the first clinical site
for its lead asset, HG-CT-1, targeting relapsed/refractory (R/R)
acute myeloid leukemia (AML) in adults. Recruitment of patients for
the trials has begun.
This Phase I trial is designed as a
dose-escalation study to evaluate the safety profile of HG-CT-1 in adult
patients with R/R AML. Key secondary objectives include assessing
the therapy's impact on the following clinical outcomes:
· Efficacy
of HG-CT-1 based
on AML-specific response criteria
· Overall survival
(OS) rates among participating subjects
· Progression-free survival
(PFS) in evaluable subjects
· Duration of response
(DoR) in those who achieve clinical responses.
These objectives are pivotal for
assessing the overall clinical impact of HG-CT-1 on patients with
R/R AML, a population with few remaining therapeutic options. The
commencement of this trial represents a major milestone for
Hemogenyx Pharmaceuticals, enabling the Company to advance this
promising therapy into clinical testing at one of the world's most
prestigious cancer research institutions.
Dr
Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals,
commented:
" The opening of our first clinical site for the Phase I trial
of HG-CT-1 is a milestone in our mission to revolutionize the
treatment landscape for relapsed and refractory acute myeloid
leukemia. This trial offers hope to patients who currently face
limited treatment options by exploring the safety and potential
efficacy of HG-CT-1. We are excited to start this pivotal
study."
About AML and CAR-T Therapy
AML, the most common type of acute
leukemia in adults, has poor survival rates (a five-year survival
rate of less than 30% in adults) and is currently treated using
chemotherapy, rather than the potentially more benign and effective
forms of therapy being developed by Hemogenyx Pharmaceuticals. The
successful development of a new therapy for AML would have a major
impact on treatment and survival rates for the disease.
CAR-T therapy is a treatment in
which a patient's own T-cells, a type of immune cell, are modified
to recognize and kill the patient's cancer cells. The procedure
involves: isolating T-cells from the patient; modifying the
isolated T-cells in a laboratory using a CAR gene construct (which
allows the cells to recognize the patient's cancer); amplifying
(growing to large numbers) the newly modified cells; and
re-introducing the cells back into the patient.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in
this announcement would have been inside information for the
purposes of Article 7 of Regulation No 596/2014 (as it forms part
of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person
responsible for arranging for the release of this announcement on
behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler,
Chief Executive Officer & Co-Founder.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as a platform technology
that it uses as an engine for novel product development.